Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938048 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL6937043 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL6939385 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL5809555 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL21877272 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL23962222 | 1.00 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL6932478 | 0.94 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL5438166 | 0.89 | ALDH1A1 (0.41) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3541324 | 0.89 | TSHR (0.43) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL3541649 | 0.89 | TSHR (0.43) | TSHRABCB11CYP3A4ADRA2BOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364101-A1 | DICLOFENAC PRODRUG AND USE OF THE SAME | Pumont Biotech Co., Ltd. (TW) | 2023-11-16 | — | — | US | disclosed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| CN-100368401-C | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2008-02-13 | — | — | CN | disclosed |
| CN-1589262-A | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2005-03-02 | — | — | CN | disclosed |
| EP-1339686-A2 | CYANOGUANIDINE PRODRUGS | Leo Pharma A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-6525077-B2 | Antiproliferative agents | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-02-25 | — | — | US | disclosed |
| US-20020165201-A1 | Cyanoguanidine prodrugs | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-11-07 | — | — | US | disclosed |
| WO-2002042265-A2 | CYANOGUANIDINE PRODRUGS | LEO PHARMA A/S (DK) | 2002-05-30 | — | — | WO | disclosed |
| US-5981558-A | ANTIMICROBIAL ACTIVITY AND ANTITUMOR ACTIVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0918058-A1 | DC 107 DERIVATIVES (1) | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364101-A1 | DICLOFENAC PRODRUG AND USE OF THE SAME | CYP2D6, CYP2C9, CYP2B6 | TSHR 3045/4885ABCB11 206/4885CYP3A4 14/4885 |
| US-20020165201-A1 | Cyanoguanidine prodrugs | CBR1, SIGMAR1, ROR1 | TSHR 134/4885ABCB11 1185/4885CYP3A4 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.